Supplementary table I- Effectiveness and tolerance of Janus kinase inhibitors for the treatment of recalcitrant atopic dermatitis in a real-life French multicenter adult cohort. Vanlerberghe et al

Published: 9 May 2022| Version 1 | DOI: 10.17632/5zw326gw6v.1
Contributor:
Julia Vanlerberghe

Description

Supplementary Table I : Characteristics of patients at baseline (before JAK inhibitor introduction)

Files

Institutions

Universite de Lille

Categories

Descriptive Table

Licence